A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

Giovanni Scambia, Domenica Lorusso, S Pignata, F Amant, R Sorio, E Breda, W Rasch, K Hernes, C Pisano, K Leunen, L Cannella, I. Vergote

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)

Abstract

Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.
Lingua originaleEnglish
pagine (da-a)1347-1353
Numero di pagine7
RivistaCancer Chemotherapy and Pharmacology
Volume68
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms

Fingerprint

Entra nei temi di ricerca di 'A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy'. Insieme formano una fingerprint unica.

Cita questo